Using our proprietary historical trial data, Lokavant conducted an analysis to investigate key predictive factors that increased or decreased risk of participant discontinuation in COVID-19 impacted clinical trials.
This paper explores how COVID-19 was not a leading predictor of discontinuation risk across the trials we analyzed. Rather, what may be more impactful to a trial’s participant discontinuation risk includes a specific sponsor’s effect, trial region, and therapeutic area.